Palatin Reports First Quarter Fiscal Year 2024 Financial Res

Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023...

Related Keywords

United States , China , South Korea , Hainan Province , Hainan , Kwangdong , Ch Ungch Ong Bukto , American , Fosun Pharma , Carl Spana , Securities Exchange , Exchange Commission , Palatin Technologies Inc , Prnewswire Palatin Technologies Inc , Kwangdong Pharmaceuticals , Enrollment Complete , Dry Eye Disease , Data Currently Expected Late , Calendar Year , Ulcerative Colitis , Analysis Targeted , Results Currently Expected , Product Revenue Increased , Dispensed Increased , First Quarter Ended September , United European Gastroenterology Week , Hypoactive Sexual Desire Disorder , Registered Direct Offering , Standard Time , Melanocortin Receptor Agonists , Palatin Technologies , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Financial Statement Data Follows , Months Ended September , Nc , Biotechnology , Medical Pharmaceuticals , Pharmaceuticals , Health Care Amp Hospitals , Earnings ,